valsartan has been researched along with Cardiomyopathy, Hypertrophic Obstructive in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 6 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Axelsson, A; Bach, RG; Becker, JR; Benson, L; Braunwald, E; Bundgaard, H; Burns, KM; Canter, C; Cirino, AL; Colan, SD; Day, SM; Ho, CY; Lakdawala, NK; Lever, HM; MacRae, CA; Margossian, R; McMurray, JJV; Mestroni, L; Murphy, AM; Orav, EJ; Owens, AT; Patel, AR; Pereira, AC; Rossano, JW; Russell, MW; Seidman, CE; Solomon, SD; Soslow, JH; Taylor, MRG; Thrush, P; Vargas, JD; Wheeler, MT; Wilmot, I; Zahka, K | 1 |
| Liuzzo, G; Volpe, M | 1 |
| Bolevich, S; Bradic, J; Filipovic, N; Govoruskina, N; Grujic, J; Jakovljevic, DG; Jakovljevic, V; Jeremic, J; Jeremic, N; MacGowan, G; Milivojevic, N; Milosavljevic, I; Nikolic Turnic, T; Okwose, N; Seklic, D; Srejovic, I; Tanaskovic, I; Velicki, L; Zivanovic, MN; Zivkovic, V | 1 |
| Axelsson Raja, A; Bach, RG; Becker, JR; Benson, L; Bundgaard, H; Canter, C; Cirino, AL; Colan, SD; Day, SM; Ho, CY; Lakdawala, NK; Lever, HM; MacRae, CA; Margossian, R; McMurray, JJV; Mestroni, L; Murphy, AM; Orav, EJ; Owens, AT; Patel, AR; Pereira, AC; Rossano, JW; Russell, MW; Seidman, CE; Solomon, SD; Soslow, JH; Taylor, MRG; Thrush, P; Vissing, CR; Wheeler, MT; Wilmot, I; Zahka, K | 1 |
| Baessler, A; Barlocco, F; Brennan, P; Jakovljevic, DG; MacGowan, GA; Maier, LS; Olivotto, I; Popovic, D; Preveden, A; Ristic, A; Tafelmeier, M; Tomberli, A; Unsoeld, B; Velicki, L; Wagner, S | 1 |
| Ammendola, E; D'Alterio, G; Gravino, R; Limongelli, G; Masarone, D; Melillo, E; Pacileo, G; Petraio, A; Valente, F; Vastarella, R; Verrengia, M | 1 |
| Holcman, K; Kostkiewicz, M; Leśniak-Sobelga, A; Podolec, P; Rubiś, P; Wiśniowska-Śmiałek, S | 1 |
| Braunwald, E; Cirino, AL; Colan, SD; Day, SM; Desai, AS; Ho, CY; Lipshultz, SE; MacRae, CA; McMurray, JJV; Orav, EJ; Shi, L; Solomon, SD | 1 |
| Atar, D; Huang, L; Jordaan, P; Kompa, AR; Krum, H; von Lueder, TG; Wang, BH; Webb, R | 1 |
| Fujita, T; Goto, A; Hirata, Y; Nagai, R; Nishimatsu, H; Oba, S; Omata, M; Satonaka, H; Suzuki, E; Takeda, R | 1 |
| Kawano, H; Koide, Y; Nakamizo, R; Seto, S; Toda, G; Yano, K | 1 |
| Gong, HP; Li, L; Ma, X; Miao, Y; Sun, H; Zhang, W; Zhang, Y; Zhong, M | 1 |
5 trial(s) available for valsartan and Cardiomyopathy, Hypertrophic Obstructive
| Article | Year |
|---|---|
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial.
Topics: Adolescent; Adult; Cardiomyopathy, Hypertrophic; Double-Blind Method; Female; Heart; Heart Failure; Humans; Male; Middle Aged; Valsartan; Young Adult | 2021 |
Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial.
Topics: Adolescent; Adult; Cardiomyopathy, Hypertrophic; Child; Female; Genetic Predisposition to Disease; Humans; Hypertrophy, Left Ventricular; Male; Valsartan; Ventricular Remodeling | 2023 |
Design of the SILICOFCM study: Effect of sacubitril/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiomyopathy, Hypertrophic; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Life Style; Male; Middle Aged; Multicenter Studies as Topic; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic; Tetrazoles; Time Factors; Valsartan; Ventricular Function, Left | 2020 |
The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial.
Topics: Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Cardiomyopathy, Hypertrophic; Child; Double-Blind Method; Genotype; Humans; Hypertrophy, Left Ventricular; Middle Aged; Mutation; Sarcomeres; Valsartan; Young Adult | 2017 |
Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Cardiomyopathy, Hypertrophic; Collagen Type I; Female; Fibrosis; Humans; Male; Middle Aged; Myocardium; Tetrazoles; Valine; Valsartan | 2005 |
7 other study(ies) available for valsartan and Cardiomyopathy, Hypertrophic Obstructive
| Article | Year |
|---|---|
VANISHing the progression of cardiac abnormalities in hypertrophic cardiomyopathy with early use of valsartan?
Topics: Cardiomyopathy, Hypertrophic; Heart Defects, Congenital; Humans; Tetrazoles; Valsartan | 2022 |
Sacubitril/valsartan reverses cardiac structure and function in experimental model of hypertension-induced hypertrophic cardiomyopathy.
Topics: Animals; Cardiomyopathy, Hypertrophic; Hypertension; Models, Theoretical; Myocytes, Cardiac; Rats; Rats, Inbred WKY; Tetrazoles; Valsartan | 2023 |
Use of sacubitril/valsartan as 'bridge to transplant' in patients with end-stage hypertrophic cardiomyopathy.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiomyopathy, Hypertrophic; Drug Combinations; Heart Failure; Humans; Stroke Volume; Valsartan; Ventricular Function, Left | 2021 |
Angiotensin receptor neprilysin inhibitor treatment is safe and potentially efficacious in end‑stage hypertrophic cardiomyopathy.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiomyopathy, Hypertrophic; Drug Combinations; Enalapril; Humans; Neprilysin; Patient Safety; Tetrazoles; Treatment Outcome; Valsartan | 2017 |
Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiomyopathy, Hypertrophic; Disease Models, Animal; Drug Combinations; Fibrosis; Male; Myocardial Infarction; Myocardium; Neprilysin; Rats; Rats, Sprague-Dawley; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2015 |
Calcineurin promotes the expression of monocyte chemoattractant protein-1 in vascular myocytes and mediates vascular inflammation.
Topics: Angiotensin II; Animals; Calcineurin; Calcium Signaling; Calcium-Calmodulin-Dependent Protein Kinases; Cardiomyopathy, Hypertrophic; Cells, Cultured; Chemokine CCL2; Cyclosporine; Femoral Artery; Gene Expression Regulation; Humans; Hyperplasia; Imidazoles; Macrophages; MAP Kinase Kinase 6; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Promoter Regions, Genetic; Protein Biosynthesis; Proteins; Pyridines; Rats; Recombinant Fusion Proteins; RNA, Messenger; Signal Transduction; Tetrazoles; Transcription, Genetic; Tunica Intima; Valine; Valsartan; Vasculitis | 2004 |
[Mechanism of reversion of myocardial interstitial fibrosis in diabetic cardiomyopathy by valsartan].
Topics: Animals; Antihypertensive Agents; Blood Pressure; Blotting, Western; Cardiomyopathy, Hypertrophic; Diabetes Mellitus, Experimental; Fibrosis; Heart; Male; Myocardium; Random Allocation; Rats; Rats, Wistar; Receptors, Angiotensin; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tetrazoles; Thrombospondin 1; Transforming Growth Factor beta; Valine; Valsartan | 2006 |